logo-loader
viewScancell Holdings PLC

Scancell signs manufacturing agreement for its Moditope anti-cancer platform

The AIM-listed firm said its Moditope platform acts by stimulating the production of CD4+ T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system

cells
Scancell said it plans to commence a phase I/II clinical trial of Moditope in the first half of 2019

Scancell Holdings Plc (LON:SCLP) has signed an agreement with The PolyPeptide Group for the manufacture of its first Moditope anti-cancer platform, Modi-1-AMPLIVANT.

The AIM-listed firm said that the contract with the independent contract manufacturer of therapeutic peptides was signed at the end of March 2018.

READ: Scancell to work with Dutch firm on first on first product for Moditope cancer immune-therapy platform

The cancer specialist said its Moditope platform acts by stimulating the production of CD4+ T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system.

Scancell said it plans to commence a phase I/II clinical trial of Modi-1-AMPLIVANT in the first half of 2019 in patients with triple-negative breast cancer, ovarian cancer and sarcomas.

Cliff Holloway, CEO of Scancell, said: “Commencing GMP manufacture is an important step in the development of our first Moditope product and is key to moving this novel therapy into the clinic in the first half of 2019.”

Quick facts: Scancell Holdings PLC

Price: 5.05 GBX

LSE:SCLP
Market: LSE
Market Cap: £23.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly. CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing...

on 5/9/19

2 min read